BioTOP Berlin-Brandenburg BioTOP Berlin Brandenburg is the central contact and coordination office for all issues concerning biotechnology in the German capital region. It is our objective to coordinate all regional activities in biotechnology by networking with all key players and to initiate specific projects in order to turn Berlin-Brandenburg into a globally leading life science cluster. The services provided by BioTOP include: For more information, including a database with comprehensive profiles of all companies and scientific work groups, please visit our website at www.biotop.de. Address: |
 |
Citigate Dewe Rogerson Citigate Dewe Rogerson is the leading international consultancy specialising exclusively in financial and corporate communications across the UK, Europe, North America and Asia. Citigate has a dedicated Pharma & Biotech team with more than 60 years combined experience in the sector and a unique mix of skills: corporate and financial PR and investor relations, finance, journalism and academic science. The team provides sector expertise and forms an integrated part of Citigate Dewe Rogerson, benefiting from the company’s overall strength and from the cross-fertilisation of ideas across sectors. The Citigate Pharma & Biotech team has an established track record in working with biotechnology companies at all stages in development. As well as core skills in financial calendar work, transactions support, financial PR and media relations, the team has extensive experience in branding, design and new media consultancy. Recent clients include global top-five biotechs, listed companies in the UK and Europe, and numerous emerging businesses in the UK, France, Germany, the Netherlands, and Scandinavia. Citigate’s Pharma & Biotech team has been involved in major corporate transactions such as IPOs, other public and private fundraisings, and M&As. We have advised on a number of IPO transactions across Europe including; METabolic EXplorer (Euronext Paris - €52 million), Algeta (Oslo Stock Exchange - €30 million), Santhera Pharmaceuticals (SWX – CH88.5 million), ThromboGenics (Euronext Brussels - €35 million), Hutchison China MediTech (AIM - £40 million), Zentiva (LSE and PSE – US $211 million), Arpida (SWX - €63 million), Inion (LSE - £35 million), TopoTarget (CSE - €30 million), BioFusion (AIM - £8.2 million) and ExonHit (Alternext - 7.3 million). |
 |
De Facto Communications De Facto Communications is the consultancy of choice if you’re looking for the best in strategic communications in life science and healthcare. We have been leaders in our field since 1989 and our reputation for informed honest advice backed by effective service delivery is second to none. Being part of the Bell Pottinger Group - the UK’s largest communications consultancy, we offer large agency reach and real international influence. We are dedicated to giving you a clear advantage in today’s increasingly competitive marketplace. For global pharmaceutical companies, the perceived value of their drug pipeline is increasingly critical to their corporate reputation. For smaller life science businesses, discovering and developing new drugs - where time to profitability is longer than in almost any other industry, reputation is entirely dependent on the credibility of management, the strength of the drug pipeline and the sustainability of the business model. At De Facto we have a huge array of experience in brand-building communications – B2C, B2B and direct to stakeholder. We work with ambitious, ground-breaking companies to help them define the very essence of their brand, then manage the complexities of building its profile in this fluid and challenging marketplace. With their wide-ranging experience, we can create bespoke account teams that exactly match your markets, audiences and communications objectives. This experience is underpinned by the ability to balance commercial, medical and regulatory environments with the attitudes and concerns of opinion leaders, patients and consumers, thereby creating awareness and bringing about changes in attitudes. We have successfully helped a variety of businesses and organisations to achieve their goals - whether communicating the benefits of a new medical device to healthcare professionals or raising awareness of new genetic markers in cardiac disease to clinicians and the general public alike. We have a dedicated team of experienced professionals who specialise in accelerating patient recruitment into our clients’ clinical studies. Working closely with clinical development teams we develop and manage direct-to-patient clinical trial recruitment and retention programmes. Each programme is strategically developed through careful analysis of the study targets and demographics and is designed for implementation at local level. By utilising previous experience and identifying potential challenges to recruitment and retention in each country, we develop a unique programme that will work for every study. Using marketing, advertising, PR and other communications tactics we not only encourage patients to participate in studies, but also support clinical investigators by maximising their motivation and making it easy for them to communicate clearly with patients. Our access to the media, the financial community, government bodies, thought leaders and regulators usually exceeds our clients’ expectations. De Facto’s team is committed to working with you as a true business partner and to building long-term relationships whether you are based in the UK, Europe or the U.S. |
Financial Dynamics FD Life Sciences Team FD’s life sciences team has established a market leading practice and now represents over 90 companies worldwide. Clients range from the largest global players through to a large number of smaller fast growing businesses. In recent years, FD has been involved in some of the most significant M&A deals in the sector – working on the GE/Amersham, Nycomed/Altana, Shire/TKT transactions as well as over 30 IPOs in continental Europe, London and New York. With the team’s integrated approach to communications, we work closely with clients on all aspects of their communications programmes both developing and implementing strategy, as well as the day–to-day activities. With a combined staff of more than 20 in the life sciences teams in London and New York (including ex bankers, lawyers and journalists) FD’s team has unrivalled expertise and experience in the global healthcare market. It is this which continues to attract significant new business to FD. |
 |
Going Public Media AG Founded in1998 GoingPublic Media AG is today one of the leading publishers of magazines on technology trends, corporate finance and capital markets. 70-80 magazines, newsletters and books are being edited, printed and distributed each year. In addition to the monthly issued “GoingPublic Magazin” and its well known yearly special editions like “Corporate Finance & Private Equity Guide” or “Biotechnology” which are largely meant as reference books, the company publishes the likewise monthly “VentureCapital Magazin” (www.venturecapital.de). It stands as a hub for the private equity and venture capital industry in German speaking Europe and addresses investors and entrepreneurs who focus on trends in technology, corporate financing and venture capital/private equity. Special topics are additionally treated in supplements and special editions (“Tech-Guide”, “Start-up” a.o.). Since 2003, GoingPublic Media AG addresses retail investors via its subsidiary Smart Investor Media GmbH and the monthly issued magazine Smart Investor. The quarterly published “HV Magazin” focuses on organizational, technical und legal trends concerning the annual shareholder meeting and is directed to the responsibles of listed companies (CFOs, investor relations managers etc.). New in 2007 is “Unternehmeredition”, which focuses quarterly on Small and Medium-sized Business Entrepreneurs. Furthermore GoingPublic Media operates the corporate publishing division GoingPublic Services. About 10 magazines and newsletters are annually distributed on behalf of well-known venture capital companies and financial institutions. Since November 2006 GoingPublic Media is listed in the open market of Frankfurt stock exchange. The complete prospectus can be found at www.goingpublic.de/ir. All publications are published in German. Contact: Markus Rieger, CEO Websites: www.goingpublic.de, www.vc-magazin.de, www.hv-magazin.de, www.smartinvestor.de, www.unternehmeredition.de |
Northbank Communications Northbank Communications is a full service communications consultancy focused on science-based companies. We believe that these companies perhaps more than most, need high quality communications to build corporate value and promote their leading edge products, technologies and services. Northbank has offices in London, Congleton (near Manchester) and Munich. We provide expert counsel to our clients through a range of specialist business consulting, communications and design services appropriate to their needs. We also offer outreach programmes to media, industry, public, financial and investment communities. We provide ongoing support through all stages of a company’s development – from start-up or early stage, through listing and beyond as a publicly quoted company. In addition, we can assist publicly funded organisations and initiatives. Our understanding of the technical, commercial and financial issues facing our clients, alongside the expertise of our team and broad network of contacts, means we are able to offer a personalised, highly effective and value for money service. |
 |
Venture Valuation Company Services Clients Contacts Further branch offices: Munich, Germany, London, Canada, Seoul, Korea |
 |